摘要
目的:探讨肺癌患者外周血中CD4+ CD25+调节性T细胞的变化及意义。方法:采用流式细胞术检测肺癌患者60例、良性肺部疾病者20例、健康体检者20例的外周血CD4+ CD25+调节性T细胞水平,同时用电化学发光法检测癌胚抗原、细胞角蛋白19片断-1和神经元特异性烯醇化酶水平。结果:肺癌组外周血CD4+ CD25+调节性T细胞占CD4+T细胞比例(20.93±4.47)%,明显高于良性肺病组(15.14±4.79)%和健康对照组(15.42±3.44)%,差异有统计学意义(P<0.01)。外周血CD4+ CD25+调节性T细胞水平与肺癌病理类型、临床分期无明显相关性,但外周血CD4+ CD25+调节性T细胞水平较低者比增高者预后好。外周血CD4+ CD25+调节性T细胞占CD4+T细胞比例对肺癌的预测价值与癌胚抗原、细胞角蛋白19片断-1相似。结论:肺癌患者外周血中CD4+ CD25+调节性T细胞水平明显增高,有可能成为肺癌预测及免疫治疗的靶点。
Objective To investigate the changes and significance of CD4＋ CD25＋ T cells （regulatory T cells） in the peripheral blood of patients with lung cancer. Methods Sixty patients with lung cancer were enrolled as the study group, twenty patients with benign pulmonary diseases and twenty healthy volunteers were as control groups. Flow cytometry was used to detect the percentage of CD4＋ CD25＋ T lymphocytes present in total CD4＋ T cells in the peripheral blood, and ECLIA was used to detect the levels of CEA, CYFRA21-1 and NSE in serum of all subjects. Results The percentages of CD4＋ CD25＋ T cells in the peripheral blood of patients with lung cancer （20.93 ± 4.47%） was significantly higher than that in benign pulmonary diseases group （15. 14%±4. 79%） and healthy control group （15.42%±3.44%）（P〈0.01）. The level of CD4＋CD25＋ T cells was not related to the pathological types or clinical staging. The patients with lower level of CD4＋ CD25＋ T cells had a better prognosis. The diagnostic value as a tumor marker of the percentage of CD4＋ CD25＋ T cells in the peripheral blood was similar to CEA and CYFRA21 1. Conclusion There is an increased proportion of regulatory T cells in patients with lung cancer, and manipulation of this subpopulation could be an important component of cancer immunotherapy.
出处
《中华实用诊断与治疗杂志》
2009年第11期1090-1093,共4页
Journal of Chinese Practical Diagnosis and Therapy
基金
广东省自然科学基金项目(06300788)
